Technical Technical Technical

Technical Update - NextGen Medicine ETF's rising from the ashes. More upside potential

Equity 5 minutes to read
KCL
Kim Cramer Larsson

Technical Analyst, Saxo Bank

Summary:  Our Head of Equity Strategy, Peter Garnry, published this excellent piece https://www.home.saxo/content/articles/equities/nextgen-medicine-basket-and-the-protein-folding-problem-04082022 about Cutting Edge Biotech companies I’ve decided to have a closer look at the three of the four related ETF’s


ARK Genomic Revolution (ARKG) was a massive bubble formed in 2020 only to implode last year. Price reached within a few dollars its pre-bubble price level from 2020. ARKG has bounced 45% and there seems to be more upside potential.
On the weekly chart it formed a Doji Morning star like bottom and reversal formation in June. (circled) . Falling trend line has been broken and the ETF is building an uptrend.

Source: Saxo Group

On the daily chart ARKG gapped higher yesterday and if closing above 39.31 it has confirmed its uptrend.
If instead it closes below 34.57 the uptrend is in jeopardy and if closing below 30.81 it is reversed. First warning of that scenario to play out would be a close below 35.75.
No strong resistance before around 200 weekly SMA. Some resistance at 49.25

Source: Saxo Group

Similar rebound picture on iShares Gold Genomics Immunology & Healthcare ETF, IDNA. The ETF has formed a Doji Evening Star bottom and reversal formation on the weekly chart. Combined with divergence on RSI the rebound picture is clear.
 

Source: Saxo Group

If closing above 33.60 the uptrend has been confirmed. RSI is above support the bullish picture and 21 and 55 SMA’s are on the rise i.e. underlying bullish short- and medium-term trend
Resistance at around $36-37. Strong resistance at around 46. .

Source: Saxo Group

The German listed iShares Healthcare Innovation ETF, 2B78 was not as hard hit last year as the two previously mentioned ETF’s. However, on the weekly chart shows a Hammer followed by a long Bullish Engulfing candle both strongly indicating bottom and reversal.

Source: Saxo Group

iShares Healthcare Innovation ETF has been in an uptrend since early July and has confirmed it with a higher close yesterday. However, RSI is falling i.e. divergence indicating we could see a correction back below the 200 SMA before uptrend is likely to resume. If RSI breaks above its falling trendline it is a strong indication of uptrend to resume
Strong resistance at 7.28. 

Source: Saxo Group

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
Full disclaimer (https://www.home.saxo/legal/disclaimer/saxo-disclaimer)
Full disclaimer (https://www.home.saxo/legal/saxoselect-disclaimer/disclaimer)

Saxo Bank (Schweiz) AG
Beethovenstrasse 33
CH-8002
Zurich
Switzerland

Contact Saxo

Select region

Switzerland
Switzerland

All trading carries risk. Losses can exceed deposits on margin products. You should consider whether you understand how our products work and whether you can afford to take the high risk of losing your money. To help you understand the risks involved we have put together a general Risk Warning series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. The KIDs can be accessed within the trading platform. Please note that the full prospectus can be obtained free of charge from Saxo Bank (Switzerland) ltd. or the issuer.

This website can be accessed worldwide however the information on the website is related to Saxo Bank (Switzerland) Ltd. All clients will directly engage with Saxo Bank (Switzerland) Ltd. and all client agreements will be entered into with Saxo Bank (Switzerland) Ltd. and thus governed by Swiss Law.

The content of this website represents marketing material and has not been notified or submitted to any supervisory authority.

If you contact Saxo Bank (Switzerland) Ltd. or visit this website, you acknowledge and agree that any data that you transmit to Saxo Bank (Switzerland) Ltd., either through this website, by telephone or by any other means of communication (e.g. e-mail), may be collected or recorded and transferred to other Saxo Bank Group companies or third parties in Switzerland or abroad and may be stored or otherwise processed by them or Saxo Bank (Switzerland) Ltd. You release Saxo Bank (Switzerland) Ltd. from its obligations under Swiss banking and securities dealer secrecies and, to the extent permitted by law, data protection laws as well as other laws and obligations to protect privacy. Saxo Bank (Switzerland) Ltd. has implemented appropriate technical and organizational measures to protect data from unauthorized processing and disclosure and applies appropriate safeguards to guarantee adequate protection of such data.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.